Marco Costa, MD, PhD
Watch to find out more about this University Hospitals physician.
President, Harrington Heart and Vascular Institute, UH Institutes
Professor, Medicine, CWRU School of Medicine
Chief Innovation Officer, University Hospitals
Director, Interventional Cardiovascular Center, University Hospitals
President, Harrington Heart and Vascular Institute, University Hospitals
UH Cleveland Medical Center
Department of Medicine-Cardiovascular Medicine
11100 Euclid Ave
UH Chagrin Highlands Health Center
3909 Orange Pl
UH Euclid Health Center
18599 Lakeshore Blvd
Interventional Cardiology, Structural Heart Disease, Cardiovascular Imaging, Endovascular Procedures, Stem Cell Therapy, Optical Coherence Tomography, Percutaneous Valve Repair, Cardiac Catheterization, Cardiovascular Medicine
Education & Training
Medical / Professional School(s):
1994, Universidade Federal de Minas Gerais, Faculdade de Medicina
1994, Internal Medicine - Universidade Federal de Minas Gerais, Faculdade de Medicina
1996, Cardiovascular Disease - Hospital Felicio Rocho
1998, Interventional Cardiology - Hospital Felicio Rocho
2000, Interventional Cardiology - Erasmus Universiteit Faculteit der Geneeskunde
1994, Cardiothoracic Anesthesia - Cleveland Clinic
Patient Satisfaction Reviews
About Our Survey
At University Hospitals, we believe in providing patients with all the information they need to make educated decisions about their health care and to choose the right doctor to meet their needs. That is why we partner with the independent patient satisfaction company Press Ganey to survey patients about their experiences at UH facilities and with UH physicians. We hold ourselves to the highest standards of care and are dedicated to creating a positive patient experience for every individual who sees a UH doctor.
There are no comments for this practitioner.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Marco Costa, MD, PhD disclosed the following Outside Relationships with Industry:
Abbott Laboratories - Consulting
Boston Scientific Corp - Consulting
Cardiokinetix - Consulting
Cordis Corporation - Consulting
Daiichi-Sankyo - Consulting
Eli Lilly Pharmaceuticals Company - Consulting
Medtronic, Inc. - Consulting
Sanofi-Aventis - Consulting
Scitech Medical, Inc. - Consulting
St Jude Medical, Inc. - Consulting
St. Jude Medical, Inc. - Consulting
Abbott Vascular - Honoraria
Genae Americas - Ownership
Genae Americas - Ownership
StemMed Inc. - Ownership